RAPID Biodynamic Haematogel
Phase 2- Indications
- Diabetic foot ulcers, Pressure ulcers, Non-healing wounds, Post-operative wounds, Palliative care wounds, Deep sternal wounds
Company intelligence / Profile preview
Biotherapy Services’ RAPID™ Biodynamic Haematogel has received MHRA approval as a first-in-class point-of-care wound care treatment classified as a medicine. The RAPID-1DFU clinical trial began in March 2019 to assess safety and efficacy for diabetic foot ulcers. Early data show the product can concentrate platelets/leukocytes from patient blood to release growth factors that stimulate cell proliferation relevant to wound healing. The trial remains active at multiple UK sites
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biotherapy Services Limited.